Skip to main content

Table 2 Clinicopathologic characteristics of all 1396 patients of lymph node negative ER+/HER2- breast cancer with RS < 18 by LRR (all percentages within columns)

From: Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up

  No LRR (n = 1383) LRR (n = 13)
RS
 Mean, median (range) 12, 12 (0–17) 11, 12 (0–17)
 RS 0–10; n (%) 500 (36.2%) 5 (38.5%)
 RS 11–17; n (%) 883 (63.8%) 8 (61.5%)
Age at diagnosis
 Mean, median (range); years 57, 57 (22–90) 55, 54 (35–79)
  < 40 years; n (%) 61 (4.4%) 2 (15.4%)
  40–49 years; n (%) 328 (23.7%) 3 (23.1%)
  ≥ 50 years; n (%) 994 (71.9%) 8 (61.5%)
Tumor size, median (range); cm 1.31, 1.2 (0.3–5.8) 1.5, 1.3 (0.5–3.5)
Multifocality; n (%) 291 (21%) 6 (46.2%)
LVI; n (%) 262 (18.9%) 4 (30.8%)
Local treatment; n (%)
 BCS only 46 (3.3%) 2 (15.4%)
 BCS and radiation therapy 923 (66.7%) 7 (53.8%)
 Total mastectomy 410 (29.6%) 4 (30.8%)
 Total mastectomy and radiation therapyb 4 (0.3%)b 0
Systemic therapy; n (%)
 Endocrine therapy only 1176 (85%) 8 (61.5%)
 Endocrine therapy and chemotherapya 165 (11.9%)a 4 (30.8%)
 No systemic therapy 42 (3%) 1 (7.7%)
Median follow-up (range); months 51.9 (0.9–108.3) 71.4 (43.2–86.8)
Time to LRR, median (range), months 36.5 (9.7–74.3)
  1. BCS breast conserving surgery, LRR locoregional recurrence, LVI lymphovascular invasion, RS recurrence score
  2. aOne patient did not complete endocrine therapy
  3. bRadiation therapy following total mastectomy was given for ductal carcinoma in situ within 1 mm of the surgical margin (n = 3), and large (7 cm) tumor (n = 1)